There are 11 additional Adimab-associated programs that are currently in Phase II or Phase III (pivotal) trials. The total number of Adimab-associated clinical programs initiated by our partners has ...

LEBANON, N.H., January 13, 2025--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it ...

LEBANON, N.H., January 14, 2025--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that five ...

There are 11 additional Adimab-associated programs that are currently in Phase II or Phase III (pivotal) trials. The total number of Adimab-associated clinical programs initiated by our partners ...

Morningstar brands and products Company Portfolio ...

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 17 new ...

LEBANON, N.H., January 13, 2025--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it ...

LEBANON, N.H., January 14, 2025--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that five ...